Table S2.
Change in mean daily bowel movements and number of flushing episodes at month 6 from baseline: efficacy analyzable set
| Pasireotide LAR n=43 | Octreotide LAR n=45 | Between treatment LSM (95% CI) | |
|---|---|---|---|
| Mean daily bowel movements (mean ± standard deviation) | |||
| na | 26 | 32 | |
| Baseline | 4.9±1.4 | 6.7±3.3 | |
| Month 6 | 3.5±1.4 | 4.0±2.3 | |
| % change | −25.1±24.0 | −36.5±29.1 | 6.9 (−8.0 to 21.9) |
| Number of flushing episodes per 14-day interval (mean ± standard deviation) | |||
| na | 28 | 29 | |
| Baseline | 74.0±50.3 | 76.6±64.5 | |
| Month 6 | 44.8±43.7 | 31.1±37.2 | |
| % change | −42.1±38.8 | −49.4±36.7 | 4.5 (−15.9 to 24.8) |
Note:
a
Number of patients analyzed.
Abbreviations: CI, confidence interval; LSM, least-squares mean; octreotide LAR, octreotide long-acting repeatable; pasireotide LAR, pasireotide long-acting release.